NZ701933A - Phenoxyethyl piperidine compounds - Google Patents

Phenoxyethyl piperidine compounds

Info

Publication number
NZ701933A
NZ701933A NZ701933A NZ70193313A NZ701933A NZ 701933 A NZ701933 A NZ 701933A NZ 701933 A NZ701933 A NZ 701933A NZ 70193313 A NZ70193313 A NZ 70193313A NZ 701933 A NZ701933 A NZ 701933A
Authority
NZ
New Zealand
Prior art keywords
piperidine compounds
methyl
present
phenoxyethyl
phenoxyethyl piperidine
Prior art date
Application number
NZ701933A
Other languages
English (en)
Inventor
Matthew Allen Schiffler
Jeremy Schulenburg York
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NZ701933A publication Critical patent/NZ701933A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/45Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ701933A 2012-06-29 2013-06-20 Phenoxyethyl piperidine compounds NZ701933A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261665951P 2012-06-29 2012-06-29
US201361779099P 2013-03-13 2013-03-13
PCT/US2013/046684 WO2014004229A1 (en) 2012-06-29 2013-06-20 Phenoxyethyl piperidine compounds

Publications (1)

Publication Number Publication Date
NZ701933A true NZ701933A (en) 2017-01-27

Family

ID=48746666

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ701933A NZ701933A (en) 2012-06-29 2013-06-20 Phenoxyethyl piperidine compounds

Country Status (42)

Country Link
US (2) US8962659B2 (OSRAM)
EP (1) EP2867207B1 (OSRAM)
JP (1) JP6127136B2 (OSRAM)
KR (1) KR101653476B1 (OSRAM)
CN (1) CN104411684B (OSRAM)
AP (1) AP2014008164A0 (OSRAM)
AR (1) AR091429A1 (OSRAM)
AU (1) AU2013280875B2 (OSRAM)
BR (1) BR112014031616B1 (OSRAM)
CA (1) CA2875569C (OSRAM)
CL (1) CL2014003535A1 (OSRAM)
CO (1) CO7151507A2 (OSRAM)
CR (1) CR20140553A (OSRAM)
CY (1) CY1119425T1 (OSRAM)
DK (1) DK2867207T3 (OSRAM)
DO (1) DOP2014000287A (OSRAM)
EA (1) EA024392B1 (OSRAM)
EC (1) ECSP14033267A (OSRAM)
ES (1) ES2644812T3 (OSRAM)
GT (1) GT201400288A (OSRAM)
HR (1) HRP20171515T1 (OSRAM)
HU (1) HUE034425T2 (OSRAM)
IL (1) IL236219A (OSRAM)
JO (1) JO3296B1 (OSRAM)
LT (1) LT2867207T (OSRAM)
MA (1) MA37686B1 (OSRAM)
ME (1) ME02840B (OSRAM)
MX (1) MX345324B (OSRAM)
MY (1) MY173878A (OSRAM)
NZ (1) NZ701933A (OSRAM)
PE (1) PE20150182A1 (OSRAM)
PH (1) PH12015500009B1 (OSRAM)
PL (1) PL2867207T3 (OSRAM)
PT (1) PT2867207T (OSRAM)
RS (1) RS56452B1 (OSRAM)
SG (1) SG11201408641UA (OSRAM)
SI (1) SI2867207T1 (OSRAM)
TN (1) TN2014000501A1 (OSRAM)
TW (1) TWI599561B (OSRAM)
UA (1) UA114325C2 (OSRAM)
WO (1) WO2014004229A1 (OSRAM)
ZA (1) ZA201408632B (OSRAM)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR091429A1 (es) * 2012-06-29 2015-02-04 Lilly Co Eli Compuestos de fenoxietil piperidina
TWI636046B (zh) * 2013-05-17 2018-09-21 美國禮來大藥廠 苯氧基乙基二氫-1h-異喹啉化合物
PL3083562T3 (pl) 2013-12-17 2018-02-28 Eli Lilly & Company Pochodne fenoksyetylowych cyklicznych amin i ich aktywność jako modulatorów receptora EP4
CR20180323A (es) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
WO2018210992A1 (en) 2017-05-18 2018-11-22 Idorsia Pharmaceuticals Ltd Pyrimidine derivatives
AU2018268311B2 (en) 2017-05-18 2022-02-10 Idorsia Pharmaceuticals Ltd Pyrimidine derivatives as PGE2 receptor modulators
EP3625224B1 (en) 2017-05-18 2021-08-04 Idorsia Pharmaceuticals Ltd N-substituted indole derivatives
US11325899B2 (en) 2017-05-18 2022-05-10 Idorsia Pharmaceuticals Ltd Benzofurane and benzothiophene derivatives as PGE2 receptor modulators
WO2018210994A1 (en) 2017-05-18 2018-11-22 Idorsia Pharmaceuticals Ltd Phenyl derivatives as pge2 receptor modulators
JP7488269B2 (ja) * 2019-01-22 2024-05-21 キーセラ・(スーチョウ)・ファーマシューティカルズ・カンパニー・リミテッド Pge2/ep4シグナル伝達を阻害する化合物、その製造方法及びその医薬における応用
WO2022102731A1 (ja) 2020-11-13 2022-05-19 小野薬品工業株式会社 Ep4拮抗薬と免疫チェックポイント阻害物質との併用によるがん治療
GB202211232D0 (en) 2022-08-02 2022-09-14 Heptares Therapeutics Ltd Prostaglandin EP4 receptor agonist compounds

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2500157C2 (de) 1975-01-03 1983-09-15 Hoechst Ag, 6230 Frankfurt N-Acyl-4-(2-aminoäthyl)-benzoesäuren, deren Salze und Ester, Verfahren zu deren Herstellung und deren Verwendung
ATE336247T1 (de) * 2002-03-18 2006-09-15 Pfizer Prod Inc Verwendung von selektiven ep4 rezeptor agonisten zur behandlung von krankheiten
MXPA05007341A (es) * 2003-01-10 2005-09-30 Hoffmann La Roche Derivados de 2-piperidona como agonistas de prostaglandina.
CA2536870C (en) * 2003-09-03 2009-10-27 Pfizer Inc. Phenyl or pyridyl amide compounds as prostaglandin e2 antagonists
US20050105732A1 (en) 2003-11-17 2005-05-19 Hutchings George T. Systems and methods for delivering pre-encrypted content to a subscriber terminal
CN1950333A (zh) * 2004-05-04 2007-04-18 辉瑞大药厂 取代的甲基芳基或杂芳基酰胺化合物
EP1756043B1 (en) 2004-05-04 2009-07-01 RaQualia Pharma Inc Ortho substituted aryl or heteroaryl amide compounds
US7592364B2 (en) * 2006-02-28 2009-09-22 Allergan, Inc. Substituted gamma lactams as therapeutic agents
WO2007121578A1 (en) 2006-04-24 2007-11-01 Merck Frosst Canada Ltd. Indole amide derivatives as ep4 receptor antagonists
AU2007260529B2 (en) 2006-06-12 2012-04-19 Merck Canada Inc. Indoline amide derivatives as EP4 receptor ligands
WO2008092860A1 (en) * 2007-01-30 2008-08-07 Janssen Pharmaceutica N.V. Bicyclic derivatives as ep4 agonists
RU2479576C9 (ru) * 2008-05-14 2014-03-10 Астеллас Фарма Инк. Амидное соединение
EP2320906B1 (en) 2008-08-14 2016-02-24 Beta Pharma Canada Inc. Heterocyclic amide derivatives as ep4 receptor antagonists
CN102770159A (zh) 2010-02-22 2012-11-07 拉夸里亚创药株式会社 Ep-4受体拮抗剂在治疗il-23介导疾病中的用途
SMT201700008T1 (it) * 2010-09-21 2017-03-08 Eisai R&D Man Co Ltd Composizione farmaceutica
DK2729445T3 (en) * 2011-07-04 2016-01-18 Rottapharm Biotech Srl CYCLIC AMINE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS
US9120824B2 (en) * 2011-07-04 2015-09-01 Rottapharm Biotech S.R.L. Cyclic amine derivatives as EP4 receptor agonists
AR091429A1 (es) * 2012-06-29 2015-02-04 Lilly Co Eli Compuestos de fenoxietil piperidina

Also Published As

Publication number Publication date
TW201412717A (zh) 2014-04-01
IL236219A (en) 2017-12-31
CA2875569A1 (en) 2014-01-03
EP2867207A1 (en) 2015-05-06
CO7151507A2 (es) 2014-12-29
AR091429A1 (es) 2015-02-04
JO3296B1 (ar) 2018-09-16
DK2867207T3 (en) 2017-09-11
CA2875569C (en) 2016-04-19
CR20140553A (es) 2015-02-04
PH12015500009A1 (en) 2015-03-02
WO2014004229A1 (en) 2014-01-03
HRP20171515T1 (hr) 2017-11-17
HUE034425T2 (en) 2018-02-28
MA37686A1 (fr) 2016-09-30
ES2644812T3 (es) 2017-11-30
SG11201408641UA (en) 2015-01-29
MY173878A (en) 2020-02-26
PH12015500009B1 (en) 2020-10-09
BR112014031616B1 (pt) 2022-06-21
EP2867207B1 (en) 2017-08-09
ECSP14033267A (es) 2015-09-30
UA114325C2 (uk) 2017-05-25
PT2867207T (pt) 2017-11-01
JP2015522018A (ja) 2015-08-03
US8962659B2 (en) 2015-02-24
GT201400288A (es) 2015-08-27
AU2013280875A1 (en) 2014-12-04
US9402838B2 (en) 2016-08-02
TN2014000501A1 (en) 2016-03-30
EA201492255A1 (ru) 2015-03-31
LT2867207T (lt) 2017-10-10
CN104411684A (zh) 2015-03-11
ME02840B (me) 2018-01-20
MA37686B1 (fr) 2017-04-28
US20150126555A1 (en) 2015-05-07
HK1203937A1 (en) 2015-11-06
RS56452B1 (sr) 2018-01-31
MX2014015953A (es) 2015-07-17
EA024392B1 (ru) 2016-09-30
CL2014003535A1 (es) 2015-05-08
MX345324B (es) 2017-01-25
PE20150182A1 (es) 2015-02-13
DOP2014000287A (es) 2015-01-31
CN104411684B (zh) 2016-08-24
SI2867207T1 (sl) 2017-10-30
IL236219A0 (en) 2015-02-01
KR20150013893A (ko) 2015-02-05
PL2867207T3 (pl) 2018-01-31
TWI599561B (zh) 2017-09-21
ZA201408632B (en) 2017-06-28
AU2013280875B2 (en) 2015-09-24
KR101653476B1 (ko) 2016-09-01
US20140005226A1 (en) 2014-01-02
BR112014031616A2 (pt) 2017-06-27
AP2014008164A0 (en) 2014-12-31
CY1119425T1 (el) 2018-03-07
JP6127136B2 (ja) 2017-05-10

Similar Documents

Publication Publication Date Title
NZ701933A (en) Phenoxyethyl piperidine compounds
JO3317B1 (ar) مركبات تترا هيدروبيرولو ثيازين
PH12016501007A1 (en) Substituted benzamides and methods of use thereof
PH12017501016B1 (en) Triazolopyrimidine compounds and uses thereof
MX2015012629A (es) Compuestos de imidazo piridina.
MX2015014298A (es) Compuestos de dihidropirido pirimidina como inhibidores de autotaxina.
NZ749557A (en) 3-alkyl-5-fluoro-4-substituted-imino-3,4-dihydropyrimidin-2(1h)-one derivatives as fungicides
MX341456B (es) Amino-quinolinas como inhibidores de cinasa.
MX2016007522A (es) Estimuladores de guanilato ciclasa soluble (sgc).
PH12016501977A1 (en) 2-AMINO-6-METHYL-4,4a,5,6-TETRAHYDROPYRANO[3,4-d][1,3]THIAZIN-8a(8H)-YL-1,3-THIAZOL-4-YL AMIDES
JO3318B1 (ar) مثبطات bace
PH12017500095A1 (en) Imidazopyridazine compounds
MX368178B (es) Compuestos de ácido dimetilbenzoico.
NZ605558A (en) Benzamide derivatives and their use as hsp90 inhibitors
NZ706772A (en) Aggrecanase inhibitors
MX2015015841A (es) Compuestos de fenoxietil dihidro-1h-isoquinolina.
MX2016002718A (es) Derivados de ceto-imidazopiridina como moduladores del receptor huerfano relacionado con receptor retinoide (porc).
MX359399B (es) Inhibidores de 17alfa-hidroxilasa/c17-20-liasa.
GB201020397D0 (en) Compounds
AU2013314244A8 (en) Novel inhibitor compounds of phosphodiesterase type 10A
MX2015002705A (es) Compuestos de piridinona para usarse en terapia fotodinamica.
MX2014009084A (es) Derivados de pirimidooxazocina como inhibidores de mtor.
PH12015501056A1 (en) 2-pyridone compound
EA201300281A3 (ru) Новый способ синтеза ивабрадина и его аддиктивных солей с фармацевтически приемлемой кислотой

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 JUN 2018 BY THOMSON REUTERS

Effective date: 20170527

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 JUN 2019 BY THOMSON REUTERS

Effective date: 20180509

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 JUN 2020 BY THOMSON REUTERS

Effective date: 20190516

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 JUN 2021 BY THOMSON REUTERS

Effective date: 20200517

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 JUN 2022 BY THOMSON REUTERS

Effective date: 20210505

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 JUN 2023 BY THOMSON REUTERS

Effective date: 20220503

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 JUN 2024 BY THOMSON REUTERS

Effective date: 20230501

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 JUN 2025 BY THOMSON REUTERS

Effective date: 20240502

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 JUN 2026 BY ANAQUA SERVICES

Effective date: 20250520